Pharma giants push for tariff clarity as ambiguity threatens EU-U.S. deal
1. Pharma firms seek clarity on tariffs under new U.S.-EU trade agreement. 2. 15% tariffs on EU pharmaceuticals could significantly raise costs for firms. 3. Potential tariff increases might risk undermining the entire trade deal. 4. Pharmaceutical products are EU's largest export to the U.S., worth $120 billion. 5. Uncertainty around tariffs creates challenges for pharma firms navigating the deal.